hrp0094p2-480 | Thyroid | ESPE2021

TBG deficiency and Central Congenital Hypothyroidism (CCH): Our experience in neonatal screening with TSH and T4

Chueca Maria J. , Grau Gema , Bertholt Laura , Artola Elena , Fernández Concepción , Sarasua Ainhoa , Rodriguez Amaia , Vela Amaia , Belza Amaia , Berrade Sara , Dura Teodoro , Alonso Pablo , Puges Laura , Diez Ignacio , Espada Mercedes , Ederra Maria , Ascunce Nieves , Porras Begoña , Rica Itxaso

Objective: Analyze CCH detection program results from 3 Autonomous Communities: TSH and total T4 (TT4) in dried blood spot (DBS) at initial screening (48 hours of life) and at retesting. Describe the characteristics of neonates with screening compatible with CCH. Consider whether TBG deficiency (TBGD) is an added difficulty in said study.Materials and Methods: Retrospective study (May 2016-May 2020) of all neonates ≥33 weeks and/or ≥1500 gr...

hrp0097rfc4.5 | Growth and syndromes (to include Turner syndrome) | ESPE2023

Real-world safety and effectiveness of vosoritide: Results from an early access program in France

Cormier-Daire Valérie , Edouard Thomas , Isidor Bertrand , Cohen Shelda , Mukherjee Swati , Pimenta Jeanne , Lhaneche Leila , Rossi Massimiliano , Schaefer Elise , Goodman Erin , Sigaudy Sabine , Baujat Geneviève

Introduction: Achondroplasia is the most common skeletal dysplasia, in which the main clinical feature is short stature. Vosoritide, the first specific treatment for achondroplasia; administered as a daily subcutaneous injection, was approved by the European Medicines Agency in August 2021 for patients aged ≥2 years until closure of epiphyses. French Health Authorities granted early access to vosoritide treatment in France on 24 June 2021, which continued u...

hrp0092lb-25 | Late Breaking Posters | ESPE2019

Low Trabecular Bone Score in Children with Inflammatory Bowel Diseases

Levy Shraga Yael , Megnazi Ophir , Modan-Moses Dalit , Tripto-Shkolnik Liana , Gruber Noah , Haberman Yael , Shouval Dror , Weiss Batia

Background: Trabecular bone score (TBS) is an emerging technology to assess bone microarchitecture of the lumbar spine. In adults, this score has been shown to be a significant predictor for osteoporotic fractures, independently of major clinical risk factors and bone mineral density (BMD), and is a recommended tool in the evaluation and management of osteoporosis, especially secondary osteoporosis. To date, only few studies evaluated TBS in the pediatric popu...

hrp0086p1-p453 | Fat Metabolism and Obesity P1 | ESPE2016

The Effect of Subclinical Hypothyroidism (SH) and Treatment of SH with L-T4 on Basal Metabolic Rate in Obese Children: A Prospective Study

Muzafferova Nigar , Bas Serpil , Atay Zeynep , Bereket Abdullah , Turan Serap

Introduction: Subclinical hypothyroidism (SH) is reported up to 20% of obese population and thyroid hormone replacement in these individuals are controversial. In this study, we aimed to determine the effect of thyroid hormones on basal metabolic rate (BMR) in obesity and, thyroid hormone replacement on BMH and weight in obese patients with SH.Method: The study was conducted in 31 obese children (15 of them had subclinical hypothyroidism) admitted to our...

hrp0082fc2.4 | Bone & Mineral | ESPE2014

Fractures in Children with Chronic Inflammatory and/or Disabling Conditions: the SNAP Study

Crabtree Nicola , Hogler Wolfgang , Shaw Nicholas

Background: The SNAP study is a prospective fracture study of children with chronic inflammatory and/or disabling conditions.Objective and Hypotheses: The overall aim of the study is to establish if there is a causal link between measured body-size related bone density and low trauma fracture.Method: 280 children, aged 5–18 years, from seven disease groups namely; acute lymphoblastic leukaemia (ALL), rheumatological disease, i...

hrp0082p1-d3-53 | Bone (1) | ESPE2014

Bone Mineral Density Evaluation in Children with Gaucher Disease

Larroude Maria Silvia , Drelichman Guillermo , Cassinelli Hamilton , Richard Lucia , Ruiz Alba , Reicher Paola , Cuello Fernanda , Lanza Victoria , Fernandez Ramiro , Maro Alejandra , Corrales Marcela , Arizo Adriana , Escobar Nicolas Fernandez , Rapetti Cristina , Donato Hugo , Chain Juan Jose , Zirone Sandra , Cedola Alejandra , Bietti Julieta , Sweri Maia

Background: Bone involvement is described as a relevant sign in patients suffering Gaucher disease (GD).Objective and hypotheses: To analyze the long-term effect of enzyme replacement therapy on bone mineral density, a retrospective observational study was conducted in a cohort of 34 GD pediatric patients (14 males, 20 females, median age 11.3 years).Method: Lumbar spine (LS) (L2–L4, N: 34) and total body (TB) (N: 24) bone min...

hrp0095p1-368 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

Gender dimorphism in transgender youth – hormonal therapy and the balance between muscle, adipose tissue and cardiometabolic alterations

Borger Ophir , Oren Asaf , Perl Liat , Yackobovitch-Gavan Michal , Sheppes Tamar , Brener Avivit , Elkon-Tamir Erella , Israeli Galit , Segev-Becker Anat , Lebenthal Ophir Yael

Context: Given the importance of sex hormones in metabolic regulation, dynamics in body composition and cardiometabolic alterations may occur in transgender persons receiving gender-affirming hormone (GAH) therapy.Objectives: Our aim was to explore the association between muscle-to-fat ratio (MFR) and the risk for metabolic syndrome components in transgender youth.Methods: In 71 tr...

hrp0097fc4.6 | Growth and syndromes (to include Turner syndrome) | ESPE2023

Persistence of Growth Promoting Effects in Infants and Toddlers with Achondroplasia: Results in Children Aged Over 2 Years Old from a Phase II Extension Study with Vosoritide

Savarirayan Ravi , Irving Melita , R Wilcox William , Harmatz Paul , Phillips John , III , E Polgreen Lynda , Tofts Louise , Ozono Keiichi , Arundel Paul , A Bacino Carlos , Basel Donald , B Bober Michael , Charrow Joel , Mochizuki Hiroshi , Kotani Yumiko , M. Saal Howard , Han Lynn , Sabir Ian , Fisheleva Elena , Huntsman-Labed Alice , Day Jonathan

Introduction: Vosoritide increases growth in children with achondroplasia aged 5–18 years (Savarirayan et al, Genet Med, 2021). We recently reported results from a phase 2, randomized, double-blind, placebo-controlled study (111-206) in young children with achondroplasia aged 3 months–5 years Here we present results from an open-label extension study (111-208) spanning up to 4 years of treatment in the children aged 2-5 years at study star...

hrp0095p1-317 | Growth and Syndromes | ESPE2022

Effects of combined treatment with rhIGF-I and metreleptin in a girl with the severe insulin resistance Rabson-Mendenhall syndrom

Genthner N. , Rakicioglu H. , Karatsiolis P. , Wudy SA , Kamrath C.

We present the case of a now 11 years old girl with the ultra-rare severe insulin resistance Rabson-Mendenhall syndrome due to the previously undescribed compound heterozygous mutations exon 16: c.2986A>G (Paternal) and intron 9: c.2029+1G>T (maternal) of the insulin receptor gene. The phenotypic findings were composed of dystrophy (birth weight 1970g, small for gestational age), hyperglycemia (up to 400mg/dl), severe acanthosis nigricans and mild cardiac septal hyperpla...

hrp0095p1-352 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Random Luteinizing Hormone Concentrations for Monitoring Central Precocious Treatment Efficacy

Zeitler Philip , M. Boldt-Houle Deborah , N. Atkinson Stuart

Background: A decrease in random LH concentration is observed after initiation of treatment for central precocious puberty (CPP), but the suitability of random LH concentrations for assessing efficacy is controversial. Although Neely et al. reported that random LH values frequently fail to demonstrate suppression to prepubertal levels,1 Lee et al. demonstrated that a cutoff of random LH <0.6 IU/l may be adequate for monitoring s...